

Mario Masarone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7444465/publications.pdf>

Version: 2024-02-01

109
papers

2,836
citations

185998

28
h-index

189595

50
g-index

114
all docs

114
docs citations

114
times ranked

4951
citing authors

#	ARTICLE	IF	CITATIONS
1	Associated screening for HCV and SARS-CoV2 infection in an urban area of Southern Italy: A cohort study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 171-173.	1.0	3
2	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	3.6	12
3	Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno. <i>Liver International</i> , 2022, 42, 1467-1469.	1.9	11
4	Screening for hepatitis C at the time of the pandemic: Need to adjust the shot. <i>Liver International</i> , 2022, 42, 1918-1919.	1.9	2
5	Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 126-135.	0.4	2
6	The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. <i>Nutrients</i> , 2021, 13, 933.	1.7	50
7	The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. <i>Nutrients</i> , 2021, 13, 1314.	1.7	34
8	Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study. <i>BMJ Open</i> , 2021, 11, e043112.	0.8	0
9	Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives. <i>Nutrients</i> , 2021, 13, 1679.	1.7	14
10	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021, 53, 677-681.	0.4	13
11	Solving the gap between HCV detection and treatment in prison. HCV-RNA testing and treatment in a cohort of new arriving convicts in Southern Italy. <i>Reviews on Recent Clinical Trials</i> , 2021, 16, .	0.4	3
12	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , 2021, 41, 2228-2232.	1.9	13
13	Viral hepatitis: Milestones, unresolved issues, and future goals. <i>World Journal of Gastroenterology</i> , 2021, 27, 4603-4638.	1.4	21
14	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. <i>Metabolomics</i> , 2021, 17, 12.	1.4	37
15	PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , 2021, 8, 734847.	1.2	10
16	Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System. <i>Frontiers in Medicine</i> , 2021, 8, 781567.	1.2	16
17	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020, 52, 937-941.	0.4	53
18	Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy. <i>Life</i> , 2020, 10, 359.	1.1	7

#	ARTICLE	IF	CITATIONS
19	The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3369.	1.2	16
20	Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program. <i>Digestive and Liver Disease</i> , 2020, 52, 541-546.	0.4	21
21	Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 26, 261-268.	0.5	20
22	The diagnostic conundrum in non-alcoholic fatty liver disease. <i>Exploration of Medicine</i> , 2020, 1, .	1.5	6
23	Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells. <i>Oncology Reports</i> , 2019, 41, 1476-1486.	1.2	26
24	Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-12.	1.9	43
25	Real-life efficacy and safety of glecaprevir/pibrentasvir in HCV-infected patients with chronic kidney disease. <i>GastroHep</i> , 2019, 1, 166.	0.3	2
26	Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3134.	1.2	39
27	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3415.	1.2	90
28	HCV point-of-care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy. <i>Liver International</i> , 2019, 39, 1845-1851.	1.9	11
29	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , 2019, 39, 1852-1859.	1.9	31
30	Preclinical evaluation of Endothelial Dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles in NAFLD. <i>Digestive and Liver Disease</i> , 2019, 51, e27-e28.	0.4	1
31	HCV-Ab sero-prevalence in persons who inject drugs in a Province of Southern Italy: results of a screening program. <i>Digestive and Liver Disease</i> , 2019, 51, e17.	0.4	0
32	Hepatitis C virus prevalence in a cohort of jailbirds in a city of Southern Italy. <i>Digestive and Liver Disease</i> , 2019, 51, e59.	0.4	0
33	Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: A systematic review and meta-analysis. <i>Liver International</i> , 2019, 39, 1292-1306.	1.9	35
34	Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease. <i>Digestive and Liver Disease</i> , 2019, 51, e66.	0.4	1
35	Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis. <i>Antiviral Therapy</i> , 2018, 23, 129-138.	0.6	33
36	HCV Genotype-3h, a Difficult-to-Diagnose Sub-Genotype in the DAA Era. <i>Antiviral Therapy</i> , 2018, 23, 605-609.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 826-837.	1.9	51
38	Virological patterns of HCV patients with failure to interferon-free regimens. <i>Journal of Medical Virology</i> , 2018, 90, 942-950.	2.5	14
39	Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study. <i>Respiratory Physiology and Neurobiology</i> , 2018, 255, 7-10.	0.7	11
40	Metabolomics in the progression of non alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2018, 50, 18.	0.4	2
41	Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. <i>Hepatology</i> , 2018, 67, 48-55.	3.6	76
42	Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate—a pilot study. <i>Internal and Emergency Medicine</i> , 2018, 13, 901-906.	1.0	3
43	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2018, 68, 33-41.	1.8	19
44	Multifactor risk evaluation in patients who have eradicated HCV infection: an interim analysis in the PITER cohort. <i>Journal of Hepatology</i> , 2018, 68, S308-S309.	1.8	0
45	Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-12.	1.9	28
46	Metabolomics in the progression of fatty liver disease. <i>Journal of Hepatology</i> , 2018, 68, S568-S569.	1.8	2
47	Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-14.	1.9	447
48	Non alcoholic fatty liver disease and eNOS dysfunction in humans. <i>BMC Gastroenterology</i> , 2017, 17, 35.	0.8	45
49	Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo Studio di	1.8	1
50	Clinical characterization and economic impact evaluation of anti-HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER). <i>Journal of Hepatology</i> , 2017, 66, S535-S536.	1.8	1
51	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
52	Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis. <i>Nutrients</i> , 2017, 9, 1074.	1.7	18
53	Adiponectin in hepatology. <i>Minerva Biotechnology and Biomolecular Research</i> , 2017, 30, .	0.3	3
54	Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. <i>PLoS ONE</i> , 2017, 12, e0178473.	1.1	79

#	ARTICLE	IF	CITATIONS
55	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	1.1	37
56	A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells. <i>In Vivo</i> , 2017, 31, 609-618.	0.6	13
57	Pharmacotherapy of alcoholic liver disease in clinical practice. <i>International Journal of Clinical Practice</i> , 2016, 70, 119-131.	0.8	24
58	New chitosan-coated liposomes for controlled release of active substances in HepG2 cells: Synthesis, biological characterization, cell viability and anti-inflammatory studies. <i>Digestive and Liver Disease</i> , 2016, 48, e236.	0.4	0
59	Liver biopsy in Type 2 Diabetes Mellitus: Steatohepatitis represents the sole feature of liver damage. <i>Digestive and Liver Disease</i> , 2016, 48, e237.	0.4	0
60	P.01.4 ENDOCAN AS SERUM MARKER OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND/OR TYPE 2 DIABETES. <i>Digestive and Liver Disease</i> , 2016, 48, e131.	0.4	0
61	Impact of SVR and Type 2 Diabetes Mellitus on liver stiffness and liver functionality in HCV infected patients with severe liver disease treated with DAA: A real life study. <i>Digestive and Liver Disease</i> , 2016, 48, e234.	0.4	0
62	Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2016, 113, 179-186.	1.1	7
63	Alcoholic Liver Disease and Hepatitis C Chronic Infection. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 201-207.	0.4	7
64	Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 159-166.	0.4	30
65	HIV Vaccine for Prevention and Cure, A Mission Possible. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 290-296.	0.4	7
66	Epidemiology and Natural History of Alcoholic Liver Disease. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 167-174.	0.4	52
67	Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 306-316.	0.4	4
68	The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. <i>European Review for Medical and Pharmacological Sciences</i> , 2016, 20, 4731-4741.	0.5	43
69	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. <i>Annals of Hepatology</i> , 2015, 14, 325-332.	0.6	3
70	<i>Helicobacter pylori</i> infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. <i>United European Gastroenterology Journal</i> , 2015, 3, 17-24.	1.6	72
71	ENOS dysfunction in Steatosis and Steatohepatitis. <i>Digestive and Liver Disease</i> , 2015, 47, e55.	0.4	0
72	Steatosis in patients with HCV chronic liver disease: Baseline results from patients enrolled in the PITER cohort study. <i>Digestive and Liver Disease</i> , 2015, 47, e224-e225.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Lung ultrasound for diagnosis of pneumonia in emergency department. Internal and Emergency Medicine, 2015, 10, 851-854.	1.0	48
74	Non Alcoholic Fatty Liver: Epidemiology and Natural History. Reviews on Recent Clinical Trials, 2015, 9, 126-133.	0.4	215
75	Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. Hepatitis Monthly, 2015, 15, e18640.	0.1	7
76	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. Annals of Hepatology, 2015, 14, 325-32.	0.6	0
77	Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy. Italian Journal of Medicine, 2014, , .	0.2	0
78	Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: results of a prospective multicentric study. Italian Journal of Medicine, 2014, 8, 176.	0.2	2
79	The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. BMC Research Notes, 2014, 7, 59.	0.6	6
80	No differences of response to telaprevir based therapy in cirrhotic and non cirrhotic patients with RVR: Real life data from South Italy. Digestive and Liver Disease, 2014, 46, e134-e135.	0.4	0
81	Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterology, 2014, 14, 31.	0.8	24
82	Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 16841.	1.4	36
83	Diaphragmatic motility assessment in COPD exacerbation, early detection of Non-Invasive Mechanical Ventilation failure: a pilot study. The Ultrasound Journal, 2014, 6, .	2.0	7
84	Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World Journal of Gastroenterology, 2014, 20, 15233.	1.4	57
85	890 HIGH PREVALENCE OF SVR TO STANDARD OF CARE THERAPY IN INJECTION DRUG USERS (IDUS): AN ITALIAN MONOCENTRIC STUDY. Journal of Hepatology, 2013, 58, S366.	1.8	0
86	Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. Medical Hypotheses, 2013, 81, 913-915.	0.8	18
87	OC-14 Prevalence of occult HBV infection reactivation in a large cohort of Non-Hodgkin Lymphoma (NHL) patients: a retrospective study. Digestive and Liver Disease, 2012, 44, S5-S6.	0.4	0
88	F-47 Clinical and genetic factors of response to antiviral treatment of chronic hepatitis C virus infection. Digestive and Liver Disease, 2012, 44, S46-S47.	0.4	0
89	Coeliac disease and C virus-related chronic hepatitis: a non association. BMC Research Notes, 2012, 5, 533.	0.6	10
90	Antiviral therapy: why does it fail in HCV-related chronic hepatitis?. Expert Review of Anti-Infective Therapy, 2011, 9, 535-543.	2.0	17

#	ARTICLE	IF	CITATIONS
91	P.1.6: CONTRAST ENHANCED ULTRASOUND (CEUS) IN THE CHARACTERIZATION OF FOCAL LESIONS IN BRIGHT LIVER OF ONCOLOGY PATIENTS. <i>Digestive and Liver Disease</i> , 2011, 43, S149-S150.	0.4	0
92	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. <i>Acta Diabetologica</i> , 2011, 48, 337-343.	1.2	22
93	Inferior vena cava collapsibility to guide fluid removal in slow continuous ultrafiltration: a pilot study. <i>Intensive Care Medicine</i> , 2010, 36, 692-696.	3.9	62
94	Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle?. <i>Digestive and Liver Disease</i> , 2010, 42, 846-847.	0.4	1
95	F.N.44 HEPATIC RETINOL BINDING PROTEIN 4 (RBP-4) LEVELS ARE SIGNIFICANTLY RELATED TO THE STEATOHEPATITIS GRADE (COMPROMISSION) BUT NOT WITH HCV INFECTION. <i>Digestive and Liver Disease</i> , 2010, 42, S49.	0.4	0
96	F.N.45 NAFLD PREVALENCE IN NEW DIAGNOSED CASES OF LIVER DISEASE IN SOUTHERN ITALY: RESULTS OF A PROSPECTIVE MULTICENTRIC STUDY. <i>Digestive and Liver Disease</i> , 2010, 42, S49.	0.4	0
97	Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563]. <i>Journal of Hepatology</i> , 2009, 50, 438.	1.8	0
98	Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: Differences and similarities. <i>World Journal of Gastroenterology</i> , 2009, 15, 462.	1.4	24
99	The Impact of Diet on Liver Fibrosis and on Response to Interferon Therapy in Patients With HCV-Related Chronic Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 3159-3166.	0.2	17
100	Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. <i>Journal of Hepatology</i> , 2008, 49, 557-563.	1.8	68
101	Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients. <i>Gut</i> , 2007, 56, 1470-1471.	6.1	12
102	[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP). <i>Journal of Hepatology</i> , 2007, 46, S238.	1.8	0
103	Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease. <i>Journal of Viral Hepatitis</i> , 2007, 14, 070501060544001-???	1.0	8
104	507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues. <i>Journal of Hepatology</i> , 2006, 44, S189.	1.8	0
105	600 Association of metabolic syndrome, diabetes, iron metabolism and steatosis in HCV and HBV related chronic hepatitis: Differences and similarities. <i>Journal of Hepatology</i> , 2006, 44, S222-S223.	1.8	0
106	Interference of diet on liver histology and on the response to interferon therapy in patients with HCV-related chronic liver disease. <i>Digestive and Liver Disease</i> , 2006, 38, S31.	0.4	0
107	The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. <i>Digestive and Liver Disease</i> , 2006, 38, 485-489.	0.4	276
108	Interleukin-10 ^{rs1082} GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2006, 45, 779-785.	1.8	54

#	ARTICLE	IF	CITATIONS
109	Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. <i>Journal of Viral Hepatitis</i> , 2006, 13, 290-296.	1.0	43